TABLE 7.
Comparative characteristics of the studied groups in terms of BPRS scores measured before the ketamine infusions.
| TRD-MDD-P (n = 17) |
TRD-BD-P (n = 18) |
P-value | |
| I infusion | 0.64401 | ||
| SD | 7.2 (2.2) | 7.3 (2.6) | |
| Range | 3.0–11.0 | 0.0–11.0 | |
| Median (IQR) | 7.0 (3.0) | 7.5 (3.0) | |
| 95% CI | [6.0; 8.3] | [6.0; 8.6] | |
| II infusion | 0.25481 | ||
| SD | 3.2 (1.0) | 3.6 (1.6) | |
| Range | 1.0–5.0 | 0.0–6.0 | |
| Median (IQR) | 3.0 (1.0) | 4.0 (2.0) | |
| 95% CI | [2.7; 3.7] | [2.8; 4.4] | |
| III infusion | 0.59741 | ||
| SD | 2.8 (0.9) | 2.9 (1.3) | |
| Range | 1.0–4.0 | 0.0–4.0 | |
| Median (IQR) | 3.0 (1.0) | 3.0 (2.0) | |
| 95% CI | [2.4; 3.3] | [2.3; 3.5] | |
| IV infusion | 0.54151 | ||
| SD | 0.7 (0.6) | 0.9 (0.8) | |
| Range | 0.0–2.0 | 0.0–2.0 | |
| Median (IQR) | 1.0 (1.0) | 1.0 (1.0) | |
| 95% CI | [0.4; 1.0] | [0.5; 1.3] | |
| V infusion | 0.98681 | ||
| SD | 0.0 (0.0) | 0.0 (0.0) | |
| Range | 0.0–0.0 | 0.0–0.0 | |
| Median (IQR) | 0.0 (0.0) | 0.0 (0.0) | |
| 95% CI | [0.0; 0.0] | [0.0; 0.0] | |
| VI infusion | 0.64401 | ||
| SD | 0.6 (0.7) | 0.5 (0.8) | |
| Range | 0.0–2.0 | 0.0–3.0 | |
| Median (IQR) | 0.0 (1.0) | 0.0 (1.0) | |
| 95% CI | [0.2; 1.0] | [0.1; 0.9] | |
| VII infusion | 0.98681 | ||
| SD | 0.0 (0.0) | 0.0 (0.0) | |
| Range | 0.0–0.0 | 0.0–0.0 | |
| Median (IQR) | 0.0 (0.0) | 0.0 (0.0) | |
| 95% CI | [0.0; 0.0] | [0.0; 0.0] | |
| Follow-up | 0.58601 | ||
| SD | 0.0 (0.0) | 0.4 (1.5) | |
| Range | 0.0–0.0 | 0.0–6.0 | |
| Median (IQR) | 0.0 (0.0) | 0.0 (0.0) | |
| 95% CI | [0.0; 0.0] | [−0.3; 1.2] |
1U Mann-Whitney; SD, standard deviation; IQR, interquartile range; TRD-MDD-P, treatment resistant major psychotic depression; TRD-BD-P, treatment resistant bipolar psychotic depression; BPRS, Brief Psychiatric Rating Scale.